The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cardiac hypertrophy and thyroid hormone signaling
Open accessAbstract
Thyroid hormone exerts a large number of influences on the cardiovascular system. Increased thyroid hormone action increases the force and speed of systolic contraction and the speed of diastolic relaxation and these are largely beneficial effects. Furthermore, thyroid hormone has marked electrophysiological effects increasing heart rate and the propensity for atrial fibrillation and these effects are largely mal-adaptive. In addition, thyroid hormone markedly increases cardiac angiogenesis and decreases vascular tone. These multiple thyroid hormone effects are largely mediated by the action of nuclear based thyroid hormone receptors (TR) the thyroid hormone receptor alpha and beta. TRalpha is the predominant isoform in the heart. Rapid nongenomic thyroid hormone effects also occur, which can be clearly demonstrated in ex-vivo experiments. Some of the most marked thyroid hormone effects in cardiac myocytes involve influences on calcium flux, with thyroid hormone promoting expression of the gene encoding the calcium pump of the sarcoplasmic reticulum (SERCa2). In contrast, in hypothyroid animals phospholamban levels, which inhibit the SERCa2 pump, are increased. In addition, marked effects are exerted on the calcium channel of the sarcoplasmic reticulum the ryanodine channel. Related to myofibrillar proteins, myosin heavy chain alpha is increased by T3 and MHC beta is decreased. Complex and interesting interactions occur between cardiac hypertrophy induced by excess thyroid hormone action and cardiac hypertrophy occurring with heart failure. The thyroid hormone mediated cardiac hypertrophy in its initial phases presents a physiological hypertrophy with increases in SERCa2 levels and decreased expression of MHC beta. In contrast, pressure overload induced heart failure leads to a "pathological" cardiac hypertrophy which is largely mediated by activation of the calcineurin system and the MAPkinases signaling system. Recent evidence indicates that heart failure can lead to a downregulation of the thyroid hormone signaling system in the heart. In the failing heart, decreases of thyroid hormone receptor levels occur. In addition, serum levels of T4 and T3 are decreased with heart failure in the frame of the non-thyroidal illness syndrome. The decrease in T3 serves as an indicator for a bad prognosis in the heart failure patient being linked to increased mortality. In animal models, it can be shown that in pressure overload-induced cardiac hypertrophy a decrease of thyroid hormone receptor levels occurs. Cardiac function can be improved by increasing expression of thyroid hormone receptors mediated by adeno-associated virus based gene transfer. The failing heart may develop a "hypothyroid" status contributing to diminished cardiac contractile function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Duntas, L. H. (2002) · Thyroid · doi:10.1089/10507250252949405 · Cited by 725
Thyroid hormone and blood pressure regulation
Danzi, S., & Klein, I. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0060-7 · Cited by 261
Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy
Moruzzi, P., Doria, E., & Agostoni, P. G. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00281-1 · Cited by 135
Siu, C.-W., Zhang, X.-H., Yung, C., Kung, A. W. C., Lau, C.-P., & Tse, H.-F. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1877 · Cited by 121
Thyroid hormone regulation of phospholamban phosphorylation in the rat heart
Ojamaa, K., Kenessey, A., & Klein, I. (2000) · Endocrinology · doi:10.1210/endo.141.6.7514 · Cited by 106
Cited by
Bozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000455 · Cited by 891
Thyroid Hormones and Cardiovascular Function and Diseases
Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., Peeters, R., Zaman, A., & Iervasi, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.045 · Cited by 515
Hypothalamus‐Pituitary‐Thyroid Axis
Ortiga‐Carvalho, T. M., Chiamolera, M. I., Pazos‐Moura, C. C., & Wondisford, F. E. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c150027 · Cited by 394
Grais, I. M., & Sowers, J. R. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.03.009 · Cited by 290
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.03.015 · Cited by 275
Metadata
- Authors
- Dillmann, W.
- Venue
- Heart Failure Reviews
- Published
- 2009-01-06
- Volume
- 15
- Issue
- 2
- Pages
- 125-132
- ISSN
- 1382-4147 (ISSN-L)
- 1573-7322
- OpenAlex
- W2012945122
- Cited by
- 199
- References
- 6
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac hypertrophy and thyroid hormone signaling. https://app.cochat.ai/papers/10.1007/s10741-008-9125-7
- The paper
- Dillmann, W. (2010). Cardiac hypertrophy and thyroid hormone signaling. Heart Failure Reviews. https://doi.org/10.1007/s10741-008-9125-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.